Meiji Yasuda Life Insurance Co Makes New $625,000 Investment in Solventum Corporation $SOLV

Meiji Yasuda Life Insurance Co acquired a new position in shares of Solventum Corporation (NYSE:SOLV) during the third quarter, HoldingsChannel reports. The institutional investor acquired 8,555 shares of the company’s stock, valued at approximately $625,000.

Other institutional investors have also modified their holdings of the company. Independent Franchise Partners LLP grew its position in shares of Solventum by 74.2% in the 2nd quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock valued at $769,098,000 after buying an additional 4,320,342 shares during the last quarter. Norges Bank purchased a new stake in Solventum in the second quarter valued at $140,495,000. Vanguard Group Inc. grew its holdings in shares of Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after purchasing an additional 867,837 shares during the last quarter. Pzena Investment Management LLC purchased a new position in shares of Solventum during the third quarter worth about $31,701,000. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Solventum by 60.3% during the third quarter. Assenagon Asset Management S.A. now owns 928,830 shares of the company’s stock worth $67,805,000 after purchasing an additional 349,463 shares during the last quarter.

Solventum Trading Down 2.1%

Shares of Solventum stock opened at $69.30 on Monday. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $88.20. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00. The company’s 50-day simple moving average is $77.62 and its 200-day simple moving average is $76.20. The firm has a market cap of $12.02 billion, a price-to-earnings ratio of 7.81, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter last year, the firm earned $1.41 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum announced that its board has authorized a share buyback plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SOLV shares. Zacks Research downgraded Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Wells Fargo & Company dropped their price target on Solventum from $86.00 to $83.00 and set an “equal weight” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. BTIG Research reiterated a “buy” rating and issued a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Finally, KeyCorp increased their price objective on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.70.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.